The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial (Q41337231)

29 September 2017

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial (English)

1 reference

29 September 2017

0 references

1 reference

1 reference

tenofovir/emtricitabine

1 reference

10

Eugènia Negredo

1 reference

29 September 2017

8

Daniel Podzamczer

1 reference

29 September 2017

Jordi Navarro

6

0 references

Adrian Curran

object named as

Adrian Curran

3

0 references

Esteban Ribera

object named as

Esteban Ribera

9

0 references

Bonaventura Clotet Sala

11

object named as

Bonaventura Clotet

1 reference

29 September 2017

12

Roger Paredes

1 reference

29 September 2017

7

Carla Estany

1 reference

29 September 2017

5

Josep M Llibre

1 reference

29 September 2017

2

María Saumoy

1 reference

29 September 2017

José R Santos

1

1 reference

29 September 2017

Isabel Bravo

4

1 reference

29 September 2017

Tenofovir/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group

13

1 reference

29 September 2017

language of work or name

English

0 references

publication date

13 April 2015

1 reference

Clinical Infectious Diseases

29 September 2017

1 reference

29 September 2017

61

1 reference

29 September 2017

403-408

1 reference

29 September 2017

3

1 reference

Lopinavir/ritonavir: a review of its use in the management of HIV infection

29 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Emtricitabine: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy o

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Association of tenofovir exposure with kidney disease risk in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

Lipid profile changes by high activity anti-retroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIV296

21 January 2018

Identifiers

DOI

10.1093/CID/CIV296

1 reference

29 September 2017

1 reference